z-logo
open-access-imgOpen Access
Genetic Variations and Gastric Cancer
Author(s) -
Chenyang Yu,
Haoyan Chen
Publication year - 2015
Publication title -
gastrointestinal tumors
Language(s) - English
Resource type - Journals
eISSN - 2296-3766
pISSN - 2296-3774
DOI - 10.1159/000431265
Subject(s) - genome wide association study , heritability , candidate gene , genetic association , cancer , genetic architecture , genetics , missing heritability problem , medicine , biology , bioinformatics , gene , genetic variants , single nucleotide polymorphism , genotype , quantitative trait locus
Background: Gastric cancer (GC) has an apparent hereditary component. However, in a large fraction of gastric cases, no known genetic syndrome or family history can be identified, suggesting the presence of ‘missing heritability' in GC etiology. Genome-wide association studies (GWAS) and traditional candidate gene studies have both led to the identification of multiple replicable common genetic variants associated with GC risk. Summary: We summarize the genetic variants associated with GC risk identified up to date. Achievements derived from translational cancer research including the following aspects: (a) contribution to the our understanding of gastric tumorigenesis, (b) guidance to individualized treatment and (c) prediction of patient prognosis. We also prospect future research direction such as post-GWAS analyses and rare variants studies. Key Message: Many genetic variants were found through GWAS or candidate gene studies, and interpreting their underlying mechanisms will help us translate risk profiles generated from these variations into use in the clinical setting for targeted screening and treatment. Practical Implications: Investigation of the potential use of genetic variations as prognostic and predictive markers is a developing field. Many people could benefit from a better understanding of genetic polymorphisms to potentially identify a priori individuals who might have the best chance of survival and therefore derive most clinical benefit from treatment. Outcomes of particular scientific interest for molecular epidemiologic studies should include overall survival, recurrence- and progression-free survival, response to treatment, and early and late toxicities stemming from chemotherapy and radiation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom